ArticleSkeletal radiology2026
Clinical impact of adopting an AI-driven opportunistic bone health screening software using routine X-ray.
Article in Skeletal radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the clinical impact of an artificial intelligence device, Rho, that opportunistically screens X-rays for low bone mineral density (BMD; DXA T-score < -1). MATERIALS AND
methodsOver 13 months, Rho analyzed X-rays from patients ≥ 50 years at a large independent health facility. Radiologists could opt to include Rho-flagged findings in their X-ray reports. DXAs that occurred within 6 months of an X-ray (from patients in the first 7 months of data collection) were categorized as being prompted by Rho ("Rho-generated") or arranged via usual standard-of-care practice ("pre-planned"), and their outcomes (diagnoses and 10-year fracture risk scores) were compared.
resultsOf 34,162 X-rays, Rho flagged 19,004 (56%) for low BMD, and radiologists included this information in 7726 (41%) reports. From the first 7 months of radiologists reporting Rho findings, initial and surveillance DXAs increased by factors of 1.8 and 1.4, respectively. Of 299 Rho-generated DXAs, 193 had low bone mass (- 2.5 < T-score < - 1) and 65 had osteoporosis. Rho-generated DXAs vs. pre-planned DXAs identified a greater proportion of patients with low BMD (87% vs. 69%; p < 0.001) and similar proportions of patients with elevated fracture risk (34% vs. 40%). The diagnostic yield was particularly marked in patients undergoing their first-ever DXA (84% vs. 60%; p < 0.001), and in males ≥ 65 years (83% vs. 45%; p < 0.001).
conclusionIncorporating Rho in radiology workflow nearly doubled initial bone health assessments and prompted additional surveillance DXA evaluations. Rho-generated DXAs captured higher rates of true low BMD than standard-of-care practices, particularly in older men.
Indexed as
Identifiers
41670644What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.